高级检索
当前位置: 首页 > 详情页

Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer.

| 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ ESCI ◇ 预警期刊

机构: [1]The West China School of Public Health and West China Fourth Hospital, Sichuan University Chengdu, China. [2]Cancer Center, The Second People's Hospital of Jiangyou Jiangyou City, China. [3]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China Chengdu, China.
出处:
ISSN:

关键词: Circulating exosomal miR-382 prognosis NSCLC

摘要:
Circulating microRNAs (miRNAs) have been demonstrated as robust and promising biomarkers for non-small cell lung cancer (NSCLC). Our aim was to determine the significance of serum exosomal miR-382 in NSCLC. Circulating exosomes were collected from 126 patients with NSCLC and 60 normal controls before treatment and one month after surgery. The circulating exosomal miR-382 expression was measured with quantitative RT-PCR (qRT-PCR) in all the participants. Our findings demonstrated that circulating exosomal miR-382 was very reduced in NSCLC. In addition, it showed high accuracy for discriminating NSCLC patients from healthy subjects. Interestingly, serum exosomal miR-382 improved the diagnostic accuracy of carcinoembryonic antigen (CEA). Moreover, its level increased significantly one month following surgical resection. Reduced circulating exosomal miR-382 was positively associated with poor clinical variables. NSCLC cases with lower serum exosomal miR-382 suffered worse overall survival (OS) and serum exosomal miR-382 was independently associated with OS. Taken together, circulating exosomal miR-382 is a robust biomarker for evaluating the progression of NSCLC. IJCEP Copyright © 2021.

语种:
被引次数:
WOS:
PubmedID:
JCR分区:
出版当年[2021]版:
最新[2023]版:
Q4 ONCOLOGY Q4 PATHOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]The West China School of Public Health and West China Fourth Hospital, Sichuan University Chengdu, China.
通讯作者:
通讯机构: [3]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China Chengdu, China. [*1]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center,School of Medicine, University of Electronic Science and Technology of China, The 55th Renming South Road, Chengdu 610044, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46424 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号